

ECHO IQ TO GAIN EXPOSURE FROM TWO LATE-BREAKING SCIENCE PRESENTATIONS AT LEADING INTERNATIONAL CARDIOLOGY CONFERENCE

Highlights:

- **Echo IQ's technology innovation to be highlighted in two late-breaking science presentations at the European Society of Cardiology Congress in Amsterdam (August 2023)**
- **Echo IQ's Chief Research and Strategy Officer to present full results from clinical trial showing effectiveness of EchoSolv™ in identifying severe aortic stenosis**
- **Echo IQ's Chief Medical Advisor to present research on impact of poor rates of detection of mitral regurgitation**

Sydney: AI and Medical Technology company Echo IQ Limited ("the Company") (ASX:EIQ) is pleased to announce that it will be gaining exposure in two late-breaking science presentations at the world-leading European Society of Cardiology Congress ("ESC") in Amsterdam, Netherlands in August. For the second year in a row, Echo IQ will be featured in this way and the Company is privileged to be gaining additional exposure to a cohort of the world's leading cardiologists and researchers in cardiology.

Professor Geoff Strange (PhD FCANZ FPHSANZ) from the University of Notre Dame, and Echo IQ Chief Research and Strategy Officer, has been invited to present: "Detect Aortic Stenosis by Echo with Artificial Intelligence" at 14:00 on 27 August 2023. This work shows how artificial intelligence and technology-aided detection of severe aortic stenosis can enhance identification of disease versus human-only detection. This presentation will include the complete results of the previously announced St Vincent's Hospital clinical study which demonstrates the effectiveness of EchoSolv™ in improving detection of aortic stenosis.

Professor David Playford (MBBS FRACP, PhD FCSANZ FESC FACC), Echo IQ's Chief Medical Officer (and Chair of Cardiology, The University of Notre Dame) has been invited to present at the same conference. He will be presenting: "MR-NEDA - Prognosis of mild to severe Mitral Regurgitation" at 14:00 on 25 August 2023. This work was completed with significant contribution from Echo IQ, using natural language processing (NLP) analysis of echocardiographic reports.

Acceptance as late-breaking science at globally significant scientific conferences is difficult to secure and is testament to the level of innovation Echo IQ is bringing to the sector as well as further validation of the potential of its core product, EchoSolv™.

Cardiovascular disease remains the world's leading cause of death and the commercial opportunities for companies that support enhanced diagnosis appear to be significant.

Comments

Echo IQ Executive Chair Andrew Grover said: "For two of our leading scientific contributors to be accepted for late-breaking science presentations at the ESC Congress this year, in addition to the exposure gained last year, is a clear and unambiguous endorsement of our research-led approach to product innovation.

ESC is well attended by senior representatives from several of Echo IQ's larger partnership target prospects. These include leading valve manufacturers as well as echocardiographic hardware and reporting companies. Echo IQ will be seeking to capitalise on this exposure to generate new commercial engagements and advance those already underway."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.